Publications by authors named "Peter A Te Boekhorst"
Background: Available therapies for myelofibrosis can exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and FLT3, induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of baseline cytopenias.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates how gender affects the symptoms and complications of myeloproliferative neoplasms (MPNs), which include polycythemia vera, essential thrombocythemia, and myelofibrosis, involving 2,006 patients.
- - Findings reveal that females are more likely to experience severe and frequent symptoms compared to males, despite similar quality of life scores, with women particularly reporting worse abdominal and microvascular symptoms.
- - Males, on the other hand, are more likely to have polycythemia vera and experience complications such as thrombocytopenia and greater red blood cell transfusion requirements, along with shorter disease duration.
Article Synopsis
- Polycythemia vera (PV) is a condition linked to serious health issues and unpleasant symptoms, and JAK inhibitor therapy has shown promise for patients who have previously used hydroxyurea (HU) and experience symptoms like splenomegaly.
- A study evaluated 1,334 PV patients to investigate how previous HU use, phlebotomy needs, and splenomegaly contribute to symptom severity.
- Findings revealed that each of these factors is associated with a significant symptom burden, and having more than one feature increases the severity of symptoms, highlighting that patients with any of these issues experience considerable discomfort.
Background: Most incidentally transfused patients receive only ABO-D-compatible transfusions and antibodies are formed in up to 8%. The effect of extended (c, C, E, K, Fy(a) , Jk(a) , and S antigens) matched (EM) and ABO-D-matched red blood cell (RBC) transfusions on the incidence of new clinically relevant RBC antibody formation after a first elective transfusion event in surgical patients was studied.
Study Design And Methods: A multicenter randomized trial was performed in nontransfused patients who were scheduled to experience a single elective transfusion event of maximal 4 RBC units.
High-dose i.v. Ig (IVIg) is a prominent immunomodulatory therapy for various autoimmune and inflammatory diseases.
View Article and Find Full Text PDFThis study describes the single center experience and long-term results of ABOi kidney transplantation using a pretransplantation protocol involving immunoadsorption combined with rituximab, intravenous immunoglobulins, and triple immune suppression. Fifty patients received an ABOi kidney transplant in the period from 2006 to 2012 with a follow-up of at least one year. Eleven antibody mediated rejections were noted of which 5 were mixed antibody and cellular mediated rejections.
View Article and Find Full Text PDFMyeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
J Clin Oncol
November 2012
Article Synopsis
- The study focused on developing an abbreviated symptom score (MPN-SAF TSS) to assess and track the most relevant symptoms experienced by patients with myeloproliferative neoplasms (MPNs), aiming to improve treatment outcomes.
- Analysis included 1,408 MPN patients and revealed significant differences in symptom scores across different MPN subtypes, with a strong correlation to overall quality of life and internal consistency.
- The MPN-SAF TSS showed potential as a reliable tool for measuring symptom burden in MPN patients, making it valuable for evaluating treatment responses in future studies.
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms. As a consequence, JAK2 inhibitors have been designed to suppress the cytokine signalling cascade caused by the constitutive activation of JAK2.
View Article and Find Full Text PDFPathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic effectiveness. We conducted a multicentre, open-label, randomized, non-inferiority trial comparing the clinical effectiveness of buffy-coat derived leukoreduced platelet concentrates (PC) stored for up to 7 d in plasma with platelets stored in platelet additive solution III (PASIII) without and with treatment with amotosalen-HCl/ultraviolet-A (UVA) photochemical pathogen reduction (PR-PASIII). Primary endpoint of the study was 1-h corrected count increment (CCI).
View Article and Find Full Text PDF